Pfizer Worldwide Research & Development, Pharmaceutical Sciences, Pfizer Inc., Groton, CT 06340, USA.
Pfizer Worldwide Research & Development, Pharmaceutical Sciences, Pfizer Inc., Groton, CT 06340, USA.
Int J Pharm. 2022 Jul 25;623:121908. doi: 10.1016/j.ijpharm.2022.121908. Epub 2022 Jun 11.
Multiparticulate formulations allow for the design of specialized pharmaceutical dosage forms that cater to the needs of a wide range of patient demographics, such as pediatric and geriatric populations, by affording control over the release rate and facilitating the formulation of fixed-dose combination drugs. Melt spray-congealing (MSC) is a method for preparing multiparticulate dosage forms from a suspension or solid solution of active pharamaceutical ingredients (API) and a molten carrier matrix. Stearyl alcohol and poloxamer 407 mixtures are widely used as carrier matrices in MSC microsphere formulations. In this report, the phase equilibria of stearyl alcohol-poloxamer 407 mixtures were investigated by generating binary phase diagrams of composition, i.e. weight/weight percent of poloxamer 407 in stearyl alcohol, and temperature in the molten form and the solid state. The phase equilibria of the molten state were characterized by H NMR measurements. The miscibility curves of stearyl alcohol-poloxamer 407 molten mixtures revealed that stearyl alcohol and poloxamer 407 are not miscible in all proportions and that miscibility substantially increases with temperature. The phase equilibria of the solid state were characterized by DSC and PXRD experiments. The phase diagrams of the solid state indicate that stearyl alcohol and poloxamer 407 crystallize and melt separately and, thus, do not form a eutectic or a single phase. The phases equilibria of the bulk mixtures were compared to the phases observed in placebo MSC microspheres and it was determined that the microspheres consist of a mixture of thermodynamically stable and metastable stearyl alcohol crystals immediately after manufacture.
多颗粒制剂允许设计专门的药物剂型,以满足广泛的患者人群的需求,如儿科和老年人群,通过控制释放速率和促进固定剂量组合药物的配方。熔融喷雾凝固(MSC)是一种从活性药物成分(API)的悬浮液或固体溶液和熔融载体基质制备多颗粒剂型的方法。硬脂醇和泊洛沙姆 407 的混合物广泛用作 MSC 微球制剂中的载体基质。在本报告中,通过生成组成的二元相图,即硬脂醇中泊洛沙姆 407 的重量/重量百分比和熔融状态和固态温度,研究了硬脂醇-泊洛沙姆 407 混合物的相平衡。熔融状态的相平衡通过 H NMR 测量来表征。硬脂醇-泊洛沙姆 407 熔融混合物的混溶性曲线表明,硬脂醇和泊洛沙姆 407 不能以任何比例混溶,并且混溶性随温度显著增加。固态相平衡通过 DSC 和 PXRD 实验来表征。固态相图表明,硬脂醇和泊洛沙姆 407 分别结晶和熔化,因此不会形成共晶或单相。对大块混合物的相平衡与安慰剂 MSC 微球中观察到的相进行了比较,结果表明微球在制造后立即由热力学稳定和亚稳硬脂醇晶体的混合物组成。